Papa presented the company’s “turnaround plan” for 2025 at J.P. Morgan. “We are focused on first stabilising the company, ...

H.C. Wainwright & Co. reaffirmed its Buy rating and $15.00 price target for Emergent BioSolutions stock (NYSE:EBS). The ...

Emergent BioSolutions (NYSE:EBS – Get Free Report) was downgraded by investment analysts at StockNews.com from a “buy” rating to a “hold” rating in a report released on Friday. Several other equities ...

BioSolutions' strategic turnaround plan and cost-cutting efforts are paving the way for profitability in 2025. Explore more details here.

After its sudden rise and precipitous fall during the COVID-19 pandemic, Emergent BioSolutions is taking measured steps as it ...

Emergent BioSolutions Inc. is a biopharmaceutical company focused on protecting and enhancing life by developing and manufacturing vaccines and antibody therapeutics that are supplied to ...

In the assessment of 12-month price targets, analysts unveil insights for Emergent BioSolutions, presenting an average target ...

Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript Emergent BioSolutions receives $50 million contract option from BARDA First mpox case linked to African outbreak reported in U.S.

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Emergent Biosolutions (EBS – Research Report), with a ...

Alongside over-the-counter NARCAN® Nasal Spray 4 mg, prescription KLOXXADO® (naloxone HCl) Nasal Spray 8 mg will expand Emergent’s ability to ...

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS – Free Report) from a hold rating to a buy rating in a report released on Tuesday morning. EBS has been the topic of several other ...

Jan. 14, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today tha This option is part of Emergent’s existing 10-year contract with BARDA for advanced development and ...